Inhibition of the Class II HMG-CoA reductase of Pseudomonas mevalonii

被引:15
|
作者
Hedl, M [1 ]
Rodwell, VW [1 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
关键词
HMG-CoA reductase; Class IIHMG-CoA reductase; Pseudomonas mevalonii; isoprenoid biosynthesis; statin drug; Lovastatin;
D O I
10.1110/ps.03597504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are two structural classes of HMG-CoA reductase, the third enzyme of the mevalonate pathway of isopentenyl diphosphate biosynthesis-the Class I enzymes of eukaryotes and the Class II enzymes of certain eubacteria. Structural requirements for ligand binding to the Class II HMG-CoA reductase of Pseudomonas mevalonii were investigated. For conversion of mevalonate to HMG-CoA the -CH3, -OH, and -CH2COO- groups on carbon 3 of mevalonate were essential for ligand recognition. The statin drug Lovastatin inhibited both the conversion of HMG-CoA to mevalonate, and the reverse of this reaction. Inhibition was competitive with respect to HMG-CoA or mevalonate and noncompetitive with respect to NADH or NAD(+). K-i values were millimolar. The over 10(4)-fold difference in statin K-i values that distinguishes the two classes of HMG-CoA reductase may result from differences in the specific contacts between the statin and residues present in the Class I enzymes but lacking in a Class II HMG-CoA reductase.
引用
收藏
页码:1693 / 1697
页数:5
相关论文
共 50 条
  • [31] ABSORPTION AND DISPOSITION OF FLUVASTATIN, AND INHIBITOR OF HMG-COA REDUCTASE, IN THE RABBIT
    TSE, FLS
    LABBADIA, D
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1992, 13 (04) : 285 - 294
  • [32] Transcription of the three HMG-CoA reductase genes of Mucor circinelloides
    Nagy, Gabor
    Farkas, Anita
    Csernetics, Arpad
    Bencsik, Otto
    Szekeres, Andras
    Nyilasi, Ildiko
    Vagvolgyi, Csaba
    Papp, Tamas
    BMC MICROBIOLOGY, 2014, 14
  • [33] ACUTE HEPATITIS INDUCED BY HMG-COA REDUCTASE INHIBITOR, LOVASTATIN
    GRIMBERT, S
    PESSAYRE, D
    DEGOTT, C
    BENHAMOU, JP
    DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (09) : 2032 - 2033
  • [34] HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice
    Zineh, Issam
    FUTURE CARDIOLOGY, 2005, 1 (02) : 191 - 206
  • [35] Kinetic characterization of an oxidative, cooperative HMG-CoA reductase from Burkholderia cenocepacia
    Schwarz, Benjamin H.
    Driver, Joseph
    Peacock, Riley B.
    Dembinski, Holly E.
    Corson, Melissa H.
    Gordon, Samuel S.
    Watson, Jeffrey M.
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2014, 1844 (02): : 457 - 464
  • [36] Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters
    Cho, Il Jin
    Ahn, Ji Yun
    Kim, Suna
    Choi, Myung Sook
    Ha, Tae Youl
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 367 (01) : 190 - 194
  • [37] HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis
    Mermis, Joel D.
    Simpson, Steven Q.
    CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (05) : 484 - 492
  • [38] Dual coenzyme specificity of Archaeoglobus fulgidus HMG-CoA reductase
    Kim, DY
    Stauffacher, CV
    Rodwell, VW
    PROTEIN SCIENCE, 2000, 9 (06) : 1226 - 1234
  • [39] HMG-CoA reductase is regulated by salinity at the level of transcription in Haloferaxvolcanii
    Kelly A. Bidle
    Thomas E. Hanson
    Koko Howell
    Jennifer Nannen
    Extremophiles, 2007, 11 : 49 - 55
  • [40] Modeling of hydrophobic tetrapeptides as a competitive inhibitor for HMG-CoA reductase
    Pak, Valeriy V.
    Sagdullaev, Shomansur Sh.
    Pak, Aleksandr, V
    Khojimatov, Olim K.
    JOURNAL OF MOLECULAR STRUCTURE, 2023, 1293